Preview

Malignant tumours

Advanced search

Treatment outcomes in patients with febrile neutropenia progressing to a critical condition

https://doi.org/10.18027/2224-5057-2019-9-3-31-37

Abstract

Purpose. To determine the spectrum of febrile neutropenia (FN) complications resulting in critical conditions in patients receiving anti-tumor therapy, and to assess the immediate results of intensive care.

Materials and Methods. This was an observational single-center study with 103 patients, who developed postcytostatic therapy febrile neutropenia progressing to a critical condition. Eligibility criteria included: anti-tumor therapy received within 29 days prior to admission to the Department of Critical and Intensive Care (DCIC) and complicated by FN; critical illness existing on admission or developing within 24 hours of admission to the DCIC; age over 16 years. Recorded data included demographics, vital signs, and test results obtained during the first 24 hours of treatment, which were required to evaluate the severity of adverse events in accordance with the Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE v5.0), the Systemic Inflammatory Response Syndrome (SIRS) criteria and the Sequential Organ Failure Assessment (SOFA) score; 30-day mortality and the subsequent anti-tumor therapy start date.

Results. Out of 5114 admissions of 3608 patients, 114 met the eligibility criteria of the study, and all necessary data were obtained for 103 subjects. Patients with solid tumors accounted for two thirds of the study sample. The mean time from start of chemotherapy to critical condition was found to be 12.64±5.61 days. In 96% of the cases, the reason for hospitalization was a suspected systemic infection leading to organic disorders. Infection was the actual cause of the critical condition only in 48.5% of cases. The inpatient mortality rate was 31%; more than 70% of survivors continued anti-tumor therapy.

Conclusion. The need to determine the cause of organic disorders, which often result from causes other than infection or sepsis as it is currently understood, is among the factors complicating the management of cancer patients whose critical condition is due to drug-induced febrile neutropenia and organ failure. The availability of intensive care ensures high short-term survival and enables further use of appropriate anti-tumor treatment.

About the Authors

G. S. Yunaev
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation

Grigoriy S. Yunaev - Head of the Department of Critical and Intensive Care/

Moscow


Competing Interests: not


I. A. Kurmukov
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation

Ildar A. Kurmukov - MD, PhD, Leading Research Associate, Department of Critical and Intensive Care/

Moscow


Competing Interests: not


References

1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68 (6): 394-424. DOI: 10.3322/caac.21492. PMID: 30207593.

2. ВОЗ. Рак. Основныефакты. 2018. URL: https://www.who.int/m/news-room/fact-sheets/detaiVcancer(датa обращения 15.08.2019) . [WHO. Cancer. Key facts. 2018. URL: https://www.who.int/ru/news-room/fact-sheets/detail/cancer (accessed 15.08.2019) ].

3. Klastersky J., de Naurois J., Rolston K., Rapoport B., Maschmeyer G., Aapro M., Herrstedt J. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016; 27 (suppl 5): v111-v118. DOI: 10.1093/annonc/mdw325. PMID: 27664247.

4. Klastersky J. Management of fever in neutropenic patients with different risks of complications. Clin Infect Dis. 2004; 39 Suppl 1: S32-7. DOI: 10.1086/383050. PMID: 15250018.

5. Rasmy A., Amal A., Fotih S., Selwi W. Febrile neutropenia in cancer patient: epidemiology, microbiology, pathophysiology and management. J Cancer Prev Curr Res. 2016; 5 (3): 00165. DOI: 10.15406/jcpcr. 2016.05.00165.

6. Ozguler M. Febrile neutropenia: an approach as an infectious disease specialist. USA: Scientific Research Publishing, Inc.; 2015: 116. ISBN-13: 978-1618961204

7. Lyman G.H., Michels S.L., Reynolds M.W., Barron R., Tomic K.S., Yu J. Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer. 2010; 116 (23): 5555-63. DOI: 10.1002/cncr.25332. PMID: 20715160.

8. Швырев С.Л., Зарубина Т. В. Информационные технологии в интенсивной терапии. М.: ИД «Менеджер здравоохранения»; 2016: 92. ISBN 978-5-903834-31-0. [Shvyrev S.L., Zarubina T.V. Information technology in ICU. M.: «Manager of health care»; 2016: 92. ISBN 978-5-903834-31-0. (In Russ.)].

9. Oken M. M., Creech R. H., Tormey D. C., Horton J., Davis T. E., McFadden E. T., Carbone P. P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5 (6): 649-55. PMID: 7165009.

10. СТСАЕ v5.0. 2017. URL: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc. htm#ctc_50 (дата обращения 20.07.2019).

11. Vincent J.L., Moreno R., Takala J., Willatts S., de Mendon^a A., Bruining H., Reinhart C.K., Suter P. M., Thijs L. G. The SOFA (Sepsis related organ failure assessment) score to describe organ dysfunction or failure. On behalf of the working group on sepsis related problems of the European society if Intensive care medicine. Intensive Care Med. 1996; 22 (7): 707-10. PMID: 8844239.

12. Bone R.C., Balk R.A., Cerra F.B., Dellinger R.P., Fein A.M., Knaus W.A., Schein R.M., Sibbald W.J. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/ SCCM Consensus Conference Committee. American College of Chest Physicians / Society of Critical Care Medicine. Chest. 1992; 101 (6): 1644-55. DOI: 10.1378/chest.101.6.1644. PMID: 1303622.

13. Курмуков И.А., Кашия Ш.Р., Обухова О.А., Пронина А. М., Юнаев Г. С. Первичная диагностика сепсиса у пациентов, получающих лекарственное лечение по поводу онкологического заболевания: сравнение критериев SIRS и SOFA. Трансляционная медицина. 2017; 4 (2): 46-51. DOI: 10.18705/2311-4495-2017-4-2-46-51. [Kurmukov I.A., Kashia S.R., Obukhova O.A., Pronina A.M., Yunayev G. S. Primary diagnosis of sepsis in patients receiving medical treatment for oncological disease: comparison of SIRS and SOFA criteria. Translational Medicine. 2017; 4 (2): 46 - 51. DOI: 10.18705/2311-4495-2017-4-2-46-51. (In Russ.)].

14. Levy M. M., Fink M. P., Marshall J.C., Abraham E., Angus D., Cook D., Cohen J., Opal S. M., Vincent J.L., Ramsay G. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003; 31 (4): 1250-6. DOI: 10.1097/01.CCM.0000050454.01978.3B. PMID: 12682500.

15. Singer M., Deutschman C.S., Seymour C.W., Shankar-Hari M., Annane D., Bauer M., Bellomo R., Bernard G. R., Chiche J.D., Coopersmith C.M., Hotchkiss R.S., Levy M.M., Marshall J.C., Martin G.S., Opal S.M., Rubenfeld G.D., van der Poll T., Vincent J.L., Angus D.C. The third international consensus definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315 (8): 801-10. DOI:10.1001/jama.2016.0287. PMID: 26903338.

16. BMJ Best Practice. Febrile neutropenia. 2019. URL: https://bestpractice.bmj.com/topics/en-gb/950 (дата обращения 10.08.2019).

17. Taplitz R.A., Kennedy E.B., Bow E.J., Crews J., Gleason C., Hawley D.K., Langston A.A., Nastoupil L.J., Rajotte M., Rolston K., Strasfeld L., Flowers C. R. Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update. J Clin Oncol. 2018; 36 (14): 1443-1453. DOI: 10.1200/JCO.2017.77.6211. PMID: 29461916.

18. Flowers C.R., Seidenfeld J., Bow E.J., Karten C., Gleason C., Hawley D.K., Kuderer N.M., Langston A.A., Marr K.A., Rolston K.V., Ramsey S. D. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013; 31 (6): 794- 810. DOI: 10.1200/JCO.2012.45.8661. PMID: 23319691.

19. Kochanek M., Schalk E., von Bergwek-Baildon M., Beutel G., Buchheidt D., Hentrich M., Henze L., Kiehl M., Liebregts T., von Lilienfeld-Toal M., Classen A., Mellinghoff S., Penack O., Piepel C., Boll B. Management of sepsis in neutropenic cancer patients: 2018 guidelines from the Infectious Diseases Working Party (AGIHO) and Intensive Care Working Party (iCHOP) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol. 2019; 98 (5): 1051-1069. DOI: 10.1007/s00277-019-03622-0. PMID: 30796468.


Review

For citations:


Yunaev G.S., Kurmukov I.A. Treatment outcomes in patients with febrile neutropenia progressing to a critical condition. Malignant tumours. 2019;9(3):31-37. (In Russ.) https://doi.org/10.18027/2224-5057-2019-9-3-31-37

Views: 1120


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2224-5057 (Print)
ISSN 2587-6813 (Online)